SynthesisArchives of dermatological research2025
Real-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis.
Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ECM formation and degradation during fibrosis, repair, and regeneration.npj metabolic health and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pathological scars are classified into hypertrophic scars and keloids, and currently have poor treatment outcomes and high recurrence rates. Bleomycin has received widespread attention in scar treatment in recent years, but there is currently no exploration on its real-world data. PubMed, Embase, and Cochrane databases were searched, and eight retrospective studies on the use of bleomycin for treatment were included, covering a total of 562 patients with keloids and hypertrophic scars. The meta-analysis results revealed that 90% of patients had significant flattening of scars after treatment with bleomycin, 5% had moderate flattening, and 4% had mild flattening. The recurrence rate after treatment was only 3%. The major adverse reaction was hyperpigmentation, with an incidence rate of 8%, and no significant ulcers or skin atrophy were reported. Subgroup analysis showed that the significant flattening rate treated with bleomycin alone was 91%, which was significantly different from the 79% treated with bleomycin in combined with triamcinolone acetonide, but the difference was not statistically significant. In addition, the significant flattening rate was 99% in Western patients and 57% in Asian patients, reflecting the impact of racial differences on treatment outcomes. There was no statistically significant difference in curative effects between males and females (RR: 0.95; P = 0.77). Overall, bleomycin has good curative effect in treating scars and has high safety, especially showing more significant effects in Western populations. However, racial differences, treatment plans, and other factors may affect the therapeutic effect of bleomycin. Future research can further explore the mechanisms of these factors and provide more personalized treatment plans for patients with scar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.